XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$26.42 USD
-2.02 (-7.10%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $26.38 -0.04 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
XOMA 26.42 -2.02(-7.10%)
Will XOMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XOMA
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
What Makes XOMA Royalty (XOMA) a New Buy Stock
Other News for XOMA
I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals
XOMA Royalty Breaks Above 200-Day Moving Average - Bullish for XOMA
XOMA Royalty to acquire cancer drug developer LAVA Therapeutics
XOMA Royalty (XOMA) to Acquire HilleVax (HLVX) in Cash Deal
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1. ...